Brief: Synairgen Says A New Clinical Trial Design Needed To Evaluate Efficacy Of SNG001 Against COVID

Synairgen

17/03/2022 07:37

March 17 (Reuters) - Synairgen PLC  SYNG.L :
    * SYNAIRGEN PLC  - SYNAIRGEN PROVIDES UPDATE ON ACTIV-2
TRIAL
    * SYNAIRGEN PLC -  US NIAID HAS HALTED ALL PATIENT
RECRUITMENT IN
ITS PHASE 2/3 COVID-19 TRIAL WHICH INCLUDED ASSESSMENT OF
SNG001.
    * SYNAIRGEN PLC - A NEW CLINICAL TRIAL DESIGN IS NEEDED TO
EVALUATE EFFICACY OF SNG001 AGAINST COVID-19.
    * SYNAIRGEN PLC - SYNAIRGEN EXPECTS TO RECEIVE PHASE 2 DATA
FROM
ACTIV-2 IN FIRST HALF OF THIS YEAR
    * SYNAIRGEN PLC - SNG001 HAS DEMONSTRATED IN VITRO ANTIVIRAL
ACTIVITY AGAINST A BROAD RANGE OF RESPIRATORY VIRUSES INCLUDING
SARS-COV-2 AND ITS VARIANTS
    * SYNAIRGEN - LEAD INVESTIGATORS FROM ACTIV-2, SYNAIRGEN IN
DISCUSSIONS TO TRY TO IDENTIFY APPROPRIATE CLINICAL TRIAL TO
CONTINUE EVALUATION OF SNG001
    * SYNAIRGEN-PHASE 3 SPRINTER TRIAL TOPLINE DATA SHOWED
ENCOURAGING
SIGNAL IN REDUCTION OF PROGRESSION TO SEVERE DISEASE, DEATH ON
TOP OF STANDARD OF CARE

Source text for Eikon:  ID:nRSQ1126Fa 
Further company coverage:  SYNG.L 

 ((Reuters.Briefs@thomsonreuters.com;))